Factor XI and Cancer: Physiopathological Linkage and Clinical PerspectivesAlfredo Mauriello, Nicola Maurea, Anna Chiara Maratea et al.|Journal of Clinical Medicine|2025Cited by 4
Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative ReviewVincenzo Quagliariello, Nicola Maurea, Massimiliano Berretta et al.|Healthcare|2025Cited by 4
54 Sacubitril–valsartan (LCZ 696) improves longitudinal strain and ejection fraction in preclinical models treated with doxorubicin through NLRP3, MyD88, and pro-fibrotic chemokinesVincenzo Quagliariello, Nicola Maurea, Simona Buccolo et al.|European Heart Journal Supplements|2021Cited by 3
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.Vincenzo Quagliariello, Nicola Maurea, Maria Laura Canale et al.|Journal of Clinical Oncology|2024Cited by 3
SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicityNicola Maurea, Vincenzo Quagliariello, Maria Laura Canale et al.|European Heart Journal|2023Cited by 3